Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018)

Cogent Biosciences' Non-Current Deffered Revenue history spans 2 years, with the latest figure at $748000.0 for Q4 2018.

  • Quarterly Non-Current Deffered Revenue fell 91.42% to $748000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $748000.0 through Dec 2018, down 91.42% year-over-year, with the annual reading at $748000.0 for FY2018, 91.42% down from the prior year.
  • Non-Current Deffered Revenue came in at $748000.0 for Q4 2018, down from $871000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $8.7 million in Q4 2017 to a low of $748000.0 in Q4 2018.